RE:RE:RE:RE:RE:RE:RE:Resistance to ADCs in the treatment of solid tumors Antibodies are responsible for tumor targeting, while agonists like ONCY's pelareorep stimulates the immune system through the enhance of new and existing TiLs, and activates innate and adaptive immunity, enabling the transformation of a "cold tumor" into a "hot tumor" and remodels the TME for the synergistic of immune checkpoint inhibitors, like tecentriq or pembrolizumab, as examples.